Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $5.5052W HIGH $17.96
Volume
595.71 K
Value Traded
6.04 M
Short % Float
20.65%
Days to Cover
5.9
-4.89%Week
-31.47%1 Month
+72.05%3 Month
+19.4%6 Month
-76.37%5 Year
-87.83%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
281.67 M
EPS (TTM)
-3.28
P/E Ratio
-
Ent. Value
89.34 M
Total Shares
28.43 M
Float Shares
26.05 M
Insiders
8.36%
Institutions
82.19%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ARCT Catalyst Timeline
Dated clinical, regulatory and corporate events for Arcturus Therapeutics Holdings Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Arcturus Therapeutics Holdings Inc.
293Total events
12Upcoming
67Tier-1 (high impact)
2017 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Topline ReadoutARCT-810Clinical Data
Interim Phase 2 results for ARCT-810 in OTC deficiency announced
Ornithine Transcarbamylase (OTC) Deficiencysource ↗
●R&D DayPresentation
Arcturus to participate in Cantor Fitzgerald 12th Annual Global Healthcare Conference fireside chat
●R&D DayPresentation
Arcturus to participate in Citi's 2026 Biopharma Back to School Conference fireside chat
●R&D DayPresentation
Arcturus to participate in Wells Fargo 21st Annual Healthcare Conference fireside chat
●Quarterly UpdateCorporate
Arcturus to report Q2 2026 financial results and provide corporate update
▲Partnership / LicenseARCT-032Corporate
Strategic collaboration with Thermo Fisher Scientific to advance ARCT-032
cystic fibrosissource ↗
◆Timing GuidanceARCT-810Presentation
ARCT-810 data and regulatory plan expected later this quarter
OTC deficiencysource ↗
▲Type C MeetingARCT-2601FDA Meeting
Type C meeting with FDA for ARCT-2601
Ornithine Transcarbamylase (OTC) Deficiencysource ↗
▲Safety Data UpdateARCT-032Clinical Data
Phase 2 third cohort (28 days, 15 mg) generally safe and well tolerated
cystic fibrosissource ↗
◆Oral PresentationPresentation
Leerink Partners 2026 Global Healthcare Conference Fireside Chat
▲Type C MeetingARCT-810FDA Meeting
FDA Type C meeting provided regulatory direction on pediatric development strategy
OTC deficiencysource ↗
◆Oral PresentationPresentation
Arcturus Therapeutics presentation at 44th Annual J.P. Morgan Healthcare Conference
▲Trial InitiationARCT-032Trial
Initiated enrollment in 12-week open label Phase 2 study for CF
cystic fibrosissource ↗
▲Type C MeetingARCT-810FDA Meeting
Received FDA Type C meeting feedback on pediatric development strategy for OTC deficiency program
ornithine transcarbamylase (OTC) deficiencysource ↗
●Enrollment UpdateARCT-032Trial
Third cohort enrolling up to six subjects for 15 mg dose daily over 28 days
Cystic Fibrosis (CF)source ↗
●Oral PresentationARCT-032Presentation
Initial findings of ARCT-032 clinical activity presented at NACFC
Cystic Fibrosis (CF)source ↗
▲Interim AnalysisARCT-032Trial
Interim Phase 2 data showed mucus plug reduction in Class I CF participants
Cystic Fibrosis (CF)source ↗
●Runway Guidance UpdateCorporate
Additional cost reductions planned in Q4 2025 to extend cash runway
◆Oral PresentationARCT-032Presentation
Phase 2 interim data from first nine participants to be presented
cystic fibrosissource ↗
▲Interim AnalysisARCT-810Trial
Positive interim Phase 2 multiple dose data for ARCT-810 in OTC deficiency
Ornithine Transcarbamylase (OTC) Deficiencysource ↗
◆Oral PresentationARCT-810Presentation
Virtual KOL Presentation on ARCT-810 Phase 2 data
Ornithine Transcarbamylase (OTC) Deficiencysource ↗
◆Interim AnalysisARCT-032Trial
ARCT-032 Phase 2 interim data from first two cohorts expected in mid-2025
cystic fibrosis (CF)source ↗
▲Runway Guidance UpdateCorporate
Cash runway extended into 2028 with re-allocation of resources
◆Interim AnalysisARCT-032Trial
Phase 2 interim data for ARCT-032 on track for Q2 2025
cystic fibrosissource ↗
◆Interim AnalysisARCT-810Trial
Phase 2 interim data for ARCT-810 on track for Q2 2025
ornithine transcarbamylase deficiencysource ↗
▲Milestone PaymentCorporate
Received initial EU approval milestone payment from CSL partnership
▲EU ApprovalKOSTAIVEApprovedEx-US Regulatory
European Commission approval for KOSTAIVE received
COVID-19source ↗
▲Manufacturing MilestoneKOSTAIVEApprovedCMC / Inspection
Meiji Seika Pharma and ARCALIS received MHLW approval for commercial manufacturing of KOSTAIVE
COVID-19source ↗
◆Enrollment CompleteARCT-032Trial
Phase 2 trial expected to complete enrollment by year end 2025
cystic fibrosissource ↗
●Timing GuidanceKOSTAIVEApprovedPresentation
KOSTAIVE U.S. BLA filing anticipated 2025
COVID-19source ↗
▲Milestone PaymentCorporate
Arcturus achieved $473.1M in upfront payments and milestones from CSL as of Dec 31, 2024
▲First Patient DosedARCT-2304Trial
First Phase 1 participant dosed for ARCT-2304 in December 2024
influenzasource ↗
◆Interim AnalysisARCT-810Trial
Phase 2 interim data for ARCT-810 on track for Q4
OTC deficiencysource ↗
●IND SubmissionARCT-032IND
IND submitted for Phase 2 trial of ARCT-032 targeting cystic fibrosis
cystic fibrosissource ↗
▲Trial InitiationARCT-810Trial
Additional Phase 2 study in the United States initiated
OTC deficiencysource ↗
▲Product LaunchKOSTAIVEApprovedPost-Market
Commercial manufacture of Kostaive on track for delivery of initial 4 million doses in Q3
COVID-19source ↗
◆EU MAA SubmissionKOSTAIVEApprovedEx-US Regulatory
European Marketing Authorization application approval decision expected Q3
COVID-19source ↗
◆Topline ReadoutARCT-2138Clinical Data
ARCT-2138 (LUNAR-FLU) Phase 1 topline immunogenicity and safety data anticipated in Q3
Influenzasource ↗
Past FDA Catalysts and PDUFA Decisions
How ARCT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | ARCT-810 | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
8
Drugs Scored
rNPV / MCap
Top Drug
Top 16%
Micro Cap(rank 106 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ARCT-810 Monoclonal antibodyNCT06488313 | OTC Deficiency | Phase 2 | RECRUITING | 9 | Sep 1, 2026 | ||||||
| ARCT-2303 Monoclonal antibodyCompletedNCT06279871 | COVID-19 | Phase 3 | COMPLETED | 1,514 | Nov 21, 2024 | ||||||
| ARCT-021 Monoclonal antibodyCompletedNCT04480957 | SARS-CoV-2 | Phase 1 | COMPLETED | 106 | Jan 29, 2021 | ||||||
| ARCT-032 Small moleculeNCT05712538 | Cystic Fibrosis | Phase 2 | COMPLETED | 72 | Jul 29, 2024 | ||||||
| ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine VaccineCompletedNCT05012943 | COVID-19 Vaccines | Phase 2 | COMPLETED | 19,474 | Jan 18, 2023 | ||||||
| ARCT-165 Monoclonal antibodyCompletedNCT05037097 | COVID-19 | Phase 1 | COMPLETED | 72 | Dec 19, 2023 | ||||||
| ARCT-2304 Monoclonal antibodyCompletedNCT06602531 | Influenza, Human | Phase 1 | COMPLETED | 212 | Dec 5, 2025 | ||||||
| ARCT-2138 Monoclonal antibodyCompletedNCT06125691 | Influenza, Human | Phase 1 | COMPLETED | 139 | Jan 7, 2025 | ||||||
| ARCT-810 Monoclonal antibodyCompletedNCT04442347 | Ornithine Transcarbamylase Deficiency | Phase 1 | COMPLETED | 46 | Apr 30, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every ARCT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ARCT-810 Fast TrackOrphanRare Pediatric | ornithine transcarbamylase deficiency | Phase 2 | 2026-09-23 | encouraging interim resultsRead More | Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery PlatformRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| MULROY DENNISOfficer (Chief Financial Officer) | Grant/Award | 100,000 100,000 held | $0.00 | 05/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ARCT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0 % (-100 %) | 197.59 K | 10.72 K | -93.87% ( -164.28 K) |
ARCT Institutional Ownership Trends
ARCT Short Interest
Shares sold short, counted twice a month.
20.65%
Short % of Float
of tradable shares sold short
5.4M
Shares Sold Short
-1.6% vs prior count
5.9 High
Days to Cover
trading days of normal volume to buy every short share back
906.9K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ARCT ranks across every disease it competes in
Competitive Position is a premium feature
See how ARCT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialARCT News
ARCT▲ +0.7%today
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026
Arcturus Therapeutics announced it will release its financial results for Q3 2026 on November 5, 2026. The earnings report will be followed by a conference call and webcast at 4:30 PM ET on the same day. The company specializes in messenger RNA medicines for liver and respiratory conditions.
Read more →ARCT▲ +6.2%on this news
Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform
Arcturus Therapeutics announced positive interim results from its Phase 2 trial of ARCT-810 for ornithine transcarbamylase deficiency. The company also unveiled its next-generation mRNA delivery platform, LUNAR 2.0™, which aims to improve therapeutic delivery. This development highlights Arcturus's commitment to advancing treatments for liver and respiratory diseases.
Read more →ARCT▼ -5.3%on this news· ran to -21% by day 3shared move
Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform
Arcturus Therapeutics Holdings Inc. is set to present Phase 2 clinical data for its ARCT-810 program targeting Ornithine transcarbamylase deficiency. The virtual presentation is scheduled for September 23, 2026, and will also cover updates on the company's mRNA liver therapeutics platform. This event highlights the company's commitment to developing treatments for rare diseases.
Read more →ARCT▲ +9.9%on this news
Arcturus Therapeutics to Participate in Upcoming Investor Conferences
Arcturus Therapeutics Holdings Inc. has announced its participation in two upcoming investor conferences. The company will be featured in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026, and at Citi's 2026 Biopharma Back to School Conference on September 9, 2026. This engagement aims to enhance investor relations and showcase their focus on messenger RNA medicines.
Read more →ARCT▲ +21.9%on this news
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress
Arcturus Therapeutics reported its financial results for Q2 2026 and highlighted advancements in its ARCT-032 Phase 2 study for cystic fibrosis. The company is actively screening and enrolling participants across various sites in the U.S. This progress reflects the company's commitment to developing therapies for rare diseases.
Read more →ARCTArcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026
Arcturus Therapeutics Holdings Inc. has announced the release of its financial results for the second quarter of 2026, scheduled for August 6, 2026. The company will also host a conference call and webcast to discuss these results at 4:30 PM Eastern Time on the same day. This event highlights Arcturus's commitment to transparency with investors.
Read more →ARCTArcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
Arcturus Therapeutics Holdings Inc. has announced its participation in the Canaccord Genuity 46th Annual Growth Conference. The event will take place on August 11, 2026, in Boston, Massachusetts, where the company will engage in a fireside chat. This presentation underscores Arcturus's commitment to advancing its messenger RNA therapeutics.
Read more →ARCT▲ +5.7%on this news
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis
Arcturus Therapeutics has announced a strategic collaboration with Thermo Fisher Scientific to advance its investigational therapy ARCT-032 for cystic fibrosis. This partnership aims to leverage Thermo Fisher's expertise in biopharmaceutical development to enhance the therapeutic potential of ARCT-032. The collaboration is expected to provide significant advancements in treatment options for cystic fibrosis patients.
Read more →ARCT▲ +6.2%on this news
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
Arcturus Therapeutics Holdings Inc. has announced its participation in the 2026 Jefferies Global Healthcare Conference. The company, known for its focus on messenger RNA medicines, aims to showcase its developments in therapeutics for liver and respiratory rare diseases. This presentation reflects Arcturus's commitment to engaging with the healthcare investment community.
Read more →ARCTArcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
Arcturus Therapeutics has reported its financial results for the first quarter of 2026, along with updates on its pipeline. The announcement highlights the company's ongoing efforts in advancing its therapeutic developments. However, specific details regarding financial performance and pipeline progress were not disclosed in the article.
Read more →ARCTArcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026
Arcturus Therapeutics is scheduled to report its first quarter financial results and provide a corporate update on May 7, 2026. The announcement indicates the company's ongoing commitment to transparency and communication with stakeholders. Further details regarding the financial performance and corporate strategies will be shared during this update.
Read more →ARCTArcturus Therapeutics to Attend Upcoming March 2026 Investor Conference
Arcturus Therapeutics Holdings Inc. will participate in the Leerink Partners 2026 Global Healthcare Conference in Miami, Florida. The company specializes in messenger RNA medicines aimed at treating rare diseases. Arcturus has a robust pipeline, including candidates for cystic fibrosis and ornithine transcarbamylase deficiency, and has developed the world's first self-amplifying mRNA COVID vaccine.
Read more →ARCTArcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress
Arcturus Therapeutics reported its financial results for Q4 and fiscal year 2025, highlighting a net loss of $65.8 million. The company announced that its ARCT-032 program is permitted to proceed into a 12-week Phase 2 study, with dosing expected to begin in the first half of 2026. Despite revenue declines, Arcturus has extended its cash runway into Q2 2028, indicating a strategic focus on its rare disease therapeutic portfolio.
Read more →ARCTArcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026
Arcturus Therapeutics Holdings Inc. will announce its financial results for Q4 and fiscal year 2025 on March 3, 2026. The company will also hold a conference call and webcast at 4:30 p.m. ET on the same day. Arcturus is known for its mRNA medicines and has a diverse pipeline targeting rare diseases and infectious diseases.
Read more →ARCTArcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Arcturus Therapeutics Holdings Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Joseph Payne will discuss the company's advancements in mRNA medicines and vaccines, highlighting their innovative technologies and ongoing collaborations. Arcturus focuses on therapeutics for rare diseases and infectious diseases.
Read more →ARCTArcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress Encouraging CF interim Phase 2 data support
Arcturus Therapeutics announced its financial results for Q3 2025, highlighting encouraging interim data for its cystic fibrosis treatment, ARCT-032. The company plans to initiate a safety and efficacy study for ARCT-032 in early 2026. Despite these positive developments, Arcturus faces challenges including a delay in the U.S. BLA filing for KOSTAIVE and a reported increase in net loss compared to the previous year, alongside significant revenue declines due to reduced collaboration activities. The firm aims to extend its cash runway through planned cost reductions.
Read more →ARCTArcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress
Arcturus Therapeutics announced its second quarter financial results and pipeline progress, highlighting an expected presentation of Phase 2 interim data for its cystic fibrosis program in September. The company reported a net loss of approximately $9.2 million for the second quarter of 2025, which, while an improvement from the previous year, indicates ongoing financial challenges. Despite declines in revenue, the firm has a strong cash position, ensuring operational sustainability into 2028. The existing trials for ARCT-810 and other programs continue as Arcturus navigates its strategic collaborations.
Read more →ARCTArcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program
Arcturus Therapeutics announced positive interim Phase 2 results for ARCT-810, an mRNA therapeutic for Ornithine Transcarbamylase (OTC) deficiency. The treatment significantly reduced glutamine levels to normal and maintained stable ammonia levels. The data, including improvements in ureagenesis function, suggest that multiple doses are safe and well tolerated. With these encouraging findings, Arcturus aims to progress towards pivotal study designs for the treatment of this rare metabolic disorder.
Read more →ARCT▲ +5.6%on this news
Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress Prioritization of mRNA therapeutics pipeline
Arcturus Therapeutics has provided a financial update for the first quarter of 2025, reporting a cash runway extension into 2028 and highlighting clinical advancements in its mRNA therapeutics pipeline, particularly for cystic fibrosis and ornithine transcarbamylase deficiency. Despite a revenue decrease compared to the prior year, the company has successfully managed its expenses, resulting in a reduced net loss for the quarter. They also noted an initial milestone payment from their partnership with CSL, reflecting positive developments in their collaborations and financial management.
Read more →ARCTArcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress
Arcturus Therapeutics has provided its financial update for Q4 and fiscal year 2024, reporting a decrease in revenue and net losses. Despite these financial challenges, the company announced progress in its clinical pipeline, specifically with ARCT-032 and ARCT-810, expecting interim Phase 2 data in Q2 2025. KOSTAIVE, their self-amplifying mRNA COVID vaccine, has received approvals for manufacturing in Europe and Japan, which could enhance its commercialization efforts. The company is maintaining a strong cash position, expected to last until the end of Q1 2027.
Read more →About Arcturus Therapeutics Holdings Inc.
Headquarters10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Founded2013
BIOPHARMAWATCH ELITE PLUS
Trade the next ARCT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime